Lupin Ltd, announced that the company has entered into a multi-year promotion and marketing agreement for the AeroChamber Plus line of products with Forest Laboratories, Inc.

Under the terms of the agreement, Lipin Pharmaceuticals, Inc, USA, will use its 50 person sales force to promote the product to pediatricians.

AeroChamber Plus is a Valved Holding Chamber (VHC) device that is used with metered dose inhalers to improve the delivery of medication to the lungs in the treatment of asthma and COPD. AeroChamber Plus also reduces the deposition of medication in the mouth and throat and makes metered close inhaler with inhalation. AeroChamber Plus is the most widely prescribed holding chamber in the United States and has been used by millions of patients since its prescriptions (IMS 2007 data) are written by pediatricians.

"We are happy to strike this alliance with Forest. While the AeroChamber Plus brand has a strong position in the Valved Holding Chamber market, we believe that this marketing alliance presents a significant opportunity for further growth of the franchise for Forest, resulting in value for both companies," said Dr Kamal Sharma, managing director, Lupin.

This agreement with Forest Laboratories, Inc reflects Lupin's commitment to bring value additions to the US market to improve the overall health of the patient population. This alliance will also extend Lupin's presence in the respiratory segment and help strengthen its franchise with pediatricians.

Lupin Pharmaceuticals Inc, head-quartered in Baltimore, Maryland, is the wholly-owned subsidiary of Mumbai-based Lupin Limited, a leading Indian Pharmaceutical company. Lupin Limited develops, manufactures and markets a wide range of quality, affordable generic and branded generic formulations and APIs for the developed and the developing markets of the world.